Vivos (RDGL) Income from Continuing Operations (2010 - 2025)
Vivos (RDGL) reported Income from Continuing Operations of 1078514.0 for Q4 2025, down 5.41% on a YoY basis from 1140165.21 in Q4 2024, and down 112.6% sequentially from 507294.0 in Q3 2025.
Vivos (RDGL) Income from Continuing Operations (2010 - 2025) Analysis & Trends
Vivos (RDGL) has 16 years of Income from Continuing Operations data on file, last reported at 1078514.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations fell 5.41% year-over-year to 1078514.0; the trailing twelve-month figure through Dec 2025 stood at 3066017.0 (down 5.35% YoY), and the FY2025 full-year result was 3066017.0, down 5.35% from the prior year.
- Income from Continuing Operations declined to 1078514.0 in Q4 2025, from 507294.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 178230.0 in Q4 2021 to a low of 1860187.0 in Q2 2021.
- A 5-year average of 693457.25 and a median of 683797.5 in 2022 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations sank 1069.29% in 2021 and jumped 64.52% in 2023, its largest moves.
- Tracing RDGL's Income from Continuing Operations over 5 years: stood at 178230.0 in 2021, then plunged by 295.92% to 705653.0 in 2022, then slumped by 52.51% to 1076219.0 in 2023, then climbed by 4.93% to 1023188.0 in 2024, then fell by 5.41% to 1078514.0 in 2025.
- Business Quant data shows RDGL's Income from Continuing Operations at 1078514.0 in Q4 2025, 507294.0 in Q3 2025, and 645513.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 184.26 Bn | 176.96 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.82 Bn | 125.94 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 108.86 Bn | 99.64 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 68.54 Bn | 67.09 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 47.53 Bn | 43.86 Bn | 1.29 Bn | 380.70 Mn |
| 6 | GE HealthCare Technologies | 28.45 Bn | 26.17 Bn | 1.98 Bn | 411.00 Mn |
| 7 | Dexcom | 28.43 Bn | 27.31 Bn | 750.30 Mn | 199.50 Mn |
| 8 | Smith & Nephew | 26.96 Bn | 26.39 Bn | - | - |
| 9 | Koninklijke Philips | 25.53 Bn | 22.41 Bn | 2.07 Bn | 273.95 Mn |
| 10 | Vivos | 27.57 Mn | 26.01 Mn | -3,105.00 | -1.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.08 Mn |
| Sep 30, 2025 | -507,294.00 |
| Jun 30, 2025 | -645,513.00 |
| Mar 31, 2025 | -834,696.00 |
| Dec 31, 2024 | -1.02 Mn |
| Sep 30, 2024 | -825,263.00 |
| Jun 30, 2024 | -503,458.00 |
| Mar 31, 2024 | -558,539.00 |
| Dec 31, 2023 | -1.08 Mn |
| Sep 30, 2023 | -667,690.00 |
| Jun 30, 2023 | -902,526.00 |
| Mar 31, 2023 | -248,318.00 |
| Dec 31, 2022 | -705,653.00 |
| Sep 30, 2022 | -277,065.00 |
| Jun 30, 2022 | -787,538.00 |
| Mar 31, 2022 | -699,905.00 |
| Dec 31, 2021 | -178,230.00 |
| Sep 30, 2021 | -201,160.00 |
| Jun 30, 2021 | -1.86 Mn |
| Mar 31, 2021 | -288,189.00 |